Supernus Pharmaceuticals SUPN Business Segments — Internal employee-related expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept supn:InternalResearchAndDevelopmentExpense.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's business segments — internal employee-related expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's business segments — internal employee-related expenses?
- Supernus Pharmaceuticals (SUPN) reported business segments — internal employee-related expenses of $11.76M in Q1 2026.
- How has Supernus Pharmaceuticals's business segments — internal employee-related expenses changed year-over-year?
- Supernus Pharmaceuticals's business segments — internal employee-related expenses increased by 12.1% year-over-year, from $10.5M to $11.76M.
- What is the long-term trend for Supernus Pharmaceuticals's business segments — internal employee-related expenses?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — internal employee-related expenses has grown at a 11.8% compound annual growth rate (CAGR), from $31.56M to $44.07M.
- What does business segments — internal employee-related expenses mean?
- Includes compensation, benefits, and related costs for personnel directly involved in the segment's operations. This reflects the human capital investment required to support the company's ongoing commercial and development activities.